Publications by authors named "Si-Yu Lei"
Article Synopsis
- A retrospective study evaluated how programmed death-ligand 1 (PD-L1) expression levels affect the effectiveness of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in patients with EGFR-mutant non-small cell lung cancer (NSCLC).
- Patients were categorized into three groups based on PD-L1 levels, and their overall response rate (ORR) and progression-free survival (PFS) were analyzed.
- Results indicated that higher PD-L1 expression was linked to shorter PFS, and patients with both TP53 mutations and high PD-L1 levels experienced the worst outcomes, suggesting that these factors together could help identify patients who might benefit less from EGFR-TKIs.
(1) Background: Afatinib has been approved for patients with non-small cell lung cancer (NSCLC) carrying major uncommon epidermal growth factor receptor gene () mutations. Dacomitinib, another second-generation tyrosine kinase inhibitor, has also shown promising potential for uncommon mutations. However, no comparative study has been conducted.
View Article and Find Full Text PDFBackground: Synergistic anti-tumor effects were observed and when immune checkpoint inhibitors (ICIs) were combined with denosumab. However, the clinical benefit and safety of this synergy have not been adequately evaluated in non-small cell lung cancer (NSCLC).
Methods: Consecutive charts of NSCLC patients with bone metastases between December 2020 and December 2021 in the Chinese National Cancer Center were reviewed.
Article Synopsis
- Surveillance systems for respiratory viruses in China need upgrades due to a lack of epidemiological data, particularly among young children with acute respiratory tract infections (ARTIs).
- A study analyzed clinical records of 7,248 hospitalized children (≤2 years) in Xiamen from 2014 to 2017, finding respiratory syncytial virus (RSV) as the most prevalent virus (22.3%), with infants under 6 months at the highest risk.
- RSV-infected infants faced greater health challenges, showing higher rates of ICU admissions (12.7%) and hospital costs ($635.36), emphasizing the need for improved immunization strategies for vulnerable infants during RSV seasons.
Background: Dacomitinib is a first-line treatment for patients with non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor () mutations; however, clinical evidence of its activity on NSCLC with complex mutations is limited.
Methods: Patients harboring complex (common mutations co-existing with uncommon mutations), or common (comparison cohort) mutations, who were treated with dacomitinib, were retrospectively evaluated in the Chinese National Cancer Center and the China PLA hospital between August 2019 and August 2021.
Results: In total, 72 patients with NSCLC harboring complex (C+U group, n=18) or common (C group, n=54) mutations and being treated with dacomitinib were enrolled.
Monitoring viral transmission and analyzing the genetic diversity of a virus are imperative to better understand its evolutionary history and the mechanism driving its evolution and spread. Especially, effective monitoring of key antigenic mutations and immune escape variants caused by these mutations has great scientific importance. Thus, to further understand the molecular evolutionary dynamics of respiratory syncytial virus (RSV) circulating in China, we analyzed nasopharyngeal swab specimens derived from hospitalized children ≤5 years old with acute respiratory tract infections (ARIs) in Xiamen during 2016 to 2019.
View Article and Find Full Text PDF